Evaluation of Functional and Morphological Retinal Changes in the Course of Systemic Aranesp Treatment in Patients With Diabetes Mellitus

Trial Profile

Evaluation of Functional and Morphological Retinal Changes in the Course of Systemic Aranesp Treatment in Patients With Diabetes Mellitus

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2015

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms EPOinDR
  • Most Recent Events

    • 23 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Planned end date changed from 1 May 2010 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 22 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top